Silo pharma announces successful production of its sp-26 ketamine implant for fibromyalgia

Analytical testing has confirmed optimal formulation for upcoming studies sarasota, fl, june 07, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a successful series of development activities for the company's sp-26 ketamine implant therapeutic targeting fibromyalgia and chronic pain. an ongoing pre-clinical research study of sp-26 is underway involving analytical testing services and small batch proof-of-concept extrusion trials for the ketamine hydrochloride (ketamine hcl) implants at 20% and 40% drug load.
SILO Ratings Summary
SILO Quant Ranking